Adverum Biotechnologies ( NASDAQ: ADVM ) has made great progress lately in advancing the use of its gene therapy, known as ixoberogene soroparvovec [Ixo-vec], which is being developed for the treatment of patients with wet age-related macular degeneration [Wet-AMD]. It is currently in